New AI model improves prediction of cancer immunotherapy success - News-Medical

Researchers at Harvard Medical School have developed a new AI model called COMPASS that improves prediction of cancer immunotherapy success by 8.5 percent compared to existing approaches. The model was described in a study published on July 3, 2026. COMPASS analyses patient data to predict which patients are likely to respond to immunotherapy treatments.

The model outperformed existing predictive models by 8.5 percent, according to the researchers. The study involved analysis of patient data from multiple clinical trials. COMPASS uses a combination of genomic and clinical data to make its predictions.

The researchers stated that the model could help clinicians better select patients for immunotherapy, potentially reducing unnecessary treatments and improving outcomes. Further validation in prospective studies is needed before clinical deployment.